JP Morgan Initiates Coverage On Structure Therapeutics with Overweight Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
JP Morgan has initiated coverage on Structure Therapeutics (NASDAQ:GPCR) with an Overweight rating and set a price target of $65.

May 21, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has initiated coverage on Structure Therapeutics with an Overweight rating and a price target of $65, indicating a positive outlook for the stock.
The initiation of coverage by a major financial institution like JP Morgan with an Overweight rating and a specific price target of $65 suggests a strong positive outlook for Structure Therapeutics. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100